AUTHORS
Meghna Naik, MS, Manjuprasanna V. Nagaraju, PhD2, Ulhas Naik, PhD3
AFFILIATIONS
1 Thomas Jefferson University, Philadelphia, Pennsylvania, United States
2 Thomas Jefferson University, Philadelphia, Pennsylvania, United States
3 Thomas Jefferson University, Philadelphia, Pennsylvania, United States
ABSTRACT
Atherosclerosis is an immunothrombotic disease that can lead to myocardial infarction and ischemic stroke, two leading causes of morbidity and mortality worldwide. Platelet activation plays a critical role in both the development of atherosclerotic plaques and thrombus formation following plaque rupture. Oxidized low-density lipoprotein (oxLDL), a major component of atherosclerotic plaques, has been shown to sensitize platelets to activation; however, the molecular mechanisms underlying this priming effect remain poorly understood. We recently demonstrated that Apoptosis Signal-Regulating Kinase 1 (ASK1), a MAP3K family member, is expressed in platelets and is robustly activated by platelet agonists, as indicated by phosphorylation at Thr845. In the present study, we investigated whether oxLDL activates ASK1 and whether ASK1 contributes to oxLDL-induced platelet sensitization. Platelets isolated from hyperlipidemic mice exhibited significantly increased activation of ASK1 and its downstream effector, p38 MAP kinase. In human platelets, oxLDL induced ASK1/p38 activation at concentrations as low as 10 μg/mL, with maximal activation observed at 100 μg/mL. In contrast, native LDL (nLDL; 10–200 μg/mL) failed to activate ASK1 or p38. ASK1/p38 activation occurred rapidly, peaking within 1 minute and returning to baseline by 5 minutes. OxLDL binding to CD36 is known to activate multiple signaling pathways, including Src family kinases (SFKs), Vav1/3, JNK2, ERK5, and ROS. To determine whether CD36 mediates oxLDL-induced ASK1 activation, we used the CD36-blocking antibody FA6-152 and platelets from CD36-deficient mice. Surprisingly, neither CD36 blockade nor genetic deletion of CD36 affected oxLDL-induced ASK1/p38 activation, indicating that this signaling pathway is independent of CD36. Likewise, pretreatment with the ROS scavenger MnTMPyP failed to inhibit ASK1 activation, suggesting that CD36-dependent ROS generation is not required.
To define the signaling pathway responsible for oxLDL-induced ASK1 activation, platelets were pretreated with pharmacological inhibitors targeting SFKs, Rho kinase, PKC, PI3K, PLC, or intracellular Ca²⁺. Inhibition of PLC or chelation of intracellular Ca²⁺ completely abolished oxLDL-induced ASK1/p38 activation, whereas inhibition of the other pathways had no effect, indicating that ASK1 activation is Ca²⁺ dependent. Consistent with these findings, oxLDL induced a robust increase in intracellular Ca²⁺. Furthermore, inhibition of Gαq, PLC, or intracellular Ca²⁺ abolished ASK1/p38 activation, supporting the involvement of a Gαq-dependent signaling pathway. However, pharmacological inhibition of known platelet G protein-coupled receptors (GPCRs) failed to suppress ASK1 activation, suggesting the involvement of a previously unrecognized Gαq-coupled receptor or signaling mechanism. OxLDL alone did not induce platelet aggregation, even at concentrations up to 200 μg/mL. However, oxLDL (20 μg/mL) synergistically enhanced platelet aggregation induced by subthreshold concentrations of ADP (2.5 μM) or epinephrine (10 μM), but not by thrombin, U46619, or collagen. Inhibition of P2Y12 (Gαi), but not P2Y1 (Gαq), completely abolished the synergistic aggregation induced by oxLDL and ADP. To determine whether ASK1 mediates this priming effect, platelets were pretreated with the selective ASK1 inhibitor GS-4997. Pretreatment with GS-4997 significantly inhibited oxLDL-mediated potentiation of ADP-induced aggregation, demonstrating that ASK1 is required for oxLDL-induced platelet priming. Interestingly, oxLDL-induced phosphatidylserine exposure, a CD36-dependent response, was unaffected by ASK1 inhibition but was abolished by inhibition of SFKs, indicating that oxLDL activates distinct signaling pathways in platelets. Finally, the combination of oxLDL and epinephrine induced robust pulmonary thromboembolism, a measure of in vivo thrombosis in mice.
Collectively, these findings demonstrate that oxLDL activates two independent signaling pathways in platelets: a CD36-dependent pathway that promotes ROS generation and phosphatidylserine exposure, and a novel Gαq/Ca²⁺-dependent ASK1/p38 signaling pathway that primes platelets for activation by Gαi/Gαz-coupled agonists. These results identify ASK1 as a key mediator of platelet hyperreactivity under hyperlipidemic conditions and a potential therapeutic target for preventing atherothrombotic complications.
DISCLOSURES
Meghna Naik, MS: No relevant conflicts of interest to declare.